• Control Bionics to acquire remaining 77.83% stake in Neuro Elite Athletics
• NeuroBounce program combines neuromuscular activation strategies with improved athletic performance
• Acquisition allows tighter integration of NeuroBounce with Control Bionics' NeuroStrip EMG technology

Control Bionics Limited has announced that its U.S. subsidiary, Control Bionics Ngage Inc. (CBN), has entered into an agreement to acquire the remaining 77.83% of Neuro Elite Athletics LLC, the U.S. company behind the NeuroBounce athletic performance program. Control Bionics initially invested in Neuro Elite Athletics in 2024, and since then, the NeuroBounce program - which combines neuromuscular activation strategies with measurable improvements in athletic explosiveness, muscle power and jumping capability - has continued to build interest across the U.S. and Australia. The acquisition will be funded through the issuance of shares in Control Bionics, with the total number of ordinary shares to be issued determined based on the company's 5-day VWAP. The acquisition represents an important step in integrating the NeuroBounce offering more closely with Control Bionics' NeuroStrip EMG technology platform and supports the company's strategy to expand into high-growth performance markets. Upon completion, Neuro Elite Athletics will become a wholly owned subsidiary of Control Bionics, with the acquisition including all intellectual property, staff, and assets of Neuro Elite Athletics.

The acquisition will allow for tighter integration of the NeuroBounce program with Control Bionics' NeuroStrip EMG technology, setting the foundation for faster rollout, deeper engagement with performance partners, and a clearer pathway to growth in the U.S. and Australia.